RNS Number : 4568S
OptiBiotix Health PLC
08 January 2025

OptiBiotix Health plc
("OptiBiotix" or the "Company")

Directorate change

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare,announces that, further to the announcement on 23 October 2024, David Blain has been appointed to the Board as Finance Director and Company Secretary effective from 7 January 2025.

David is a member of the Institute of Chartered Accountants in England & Wales and has extensive financial, commercial and Board experience in a number of private and public companies, including Iksuda Therapeutics Ltd, Applied Graphene Materials plc, Nanoco Group plc and Inspired Capital plc (formerly Renovo Group plc). Mr Blain is currently Financial Director (non-board position) at Iksuda Therapeutics Ltd.

David's appointment to this part-time role will see him work closely with the OptiBiotix team to support thefocus on driving each business unit and the Group to profitability.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of David Jonathan Blain (aged 63):

Current Directorships	**Previous Directorships held in the past five years**
Blain Associates Limited	Applied Graphene Materials Limited (formerly Applied Graphene Materials plc)
	Applied Graphene Materials LLC
	Applied Graphene Ventures Limited
	Universal Matter GBR Ltd (formerly Applied Graphene Materials UK Limited)

David Blain does not hold any ordinary shares, options or warrants over new ordinary shares in the Company.

There is no further information regarding David Blain required to be disclosed under the AIM Rules.

Stephen O'Hara, CEO of OptiBiotix commented:*"We are pleased to confirm theappointment of David as Finance Director and Company Secretary. The appointment reflects the Board's focus on managing costs and building revenues to create profitable business units and an international business with well-known global brands."*

The Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

OptiBiotix Health plc — www.optibiotix.com
Neil Davidson, Chairman — *Contact via Walbrook below*
Stephen O'Hara, Chief Executive

Cairn Financial Advisers LLP (NOMAD) — Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti

Peterhouse Capital Limited (Joint Broker) — Tel: 020 7220 9797
Duncan Vasey / Lucy Williams

Walbrook PR Ltd — Mob: 07876 741 001
Anna Dunphy

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAZDLFBEFLEBBK